Related Experiment Video
Updated: Nov 14, 2025
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
Generation of Phosphopeptide-Specific T Cell Lines as Tools for Melanoma Immunotherapy
Rebecca C Obeng1, Angela L Ambakhutwala2
1Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. robeng@northwestern.edu.
Abstract:
The importance of tumor-associated antigen-specific T cells in the effective control of cancer has been highlighted by recent advances in cancer immunotherapies that target the programmed cell death-1 (PD-1) pathway or that utilize modified T cell receptors. Phosphopeptide-specific T cells are of interest because they recognize a new class of tumor antigens that are derived from proteins relevant for cancer development and growth. These T cell lines or their antigen receptors can be used in combination with other forms of therapy to improve the immune response and survival of cancer patients. We describe here a protocol for the generation of human and transgenic murine phosphopeptide-specific T cells lines as tools for investigating T cell reactivity against melanoma phosphoantigens displayed by HLA-A*0201.
Insights
Researchers developed a method to generate phosphopeptide-specific T cells. These T cells recognize novel tumor antigens and can be used to improve cancer immunotherapy and patient survival.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor-associated antigen-specific T cells are crucial for effective cancer control.
- Recent immunotherapies targeting the programmed cell death-1 (PD-1) pathway or T cell receptors have shown promise.
- Phosphopeptide antigens represent a new class of tumor antigens derived from proteins vital for cancer development.
Purpose of the Study:
- To describe a protocol for generating human and transgenic murine phosphopeptide-specific T cell lines.
- To create tools for investigating T cell reactivity against specific melanoma phosphoantigens.
- To advance the understanding of T cell responses in cancer immunology.
Main Methods:
- Generation of phosphopeptide-specific T cell lines from human and transgenic murine sources.
- Utilizing phosphopeptide antigens derived from cancer-relevant proteins.
- Focusing on T cell recognition of phosphoantigens presented by HLA-A*0201.
Main Results:
- Successful generation of phosphopeptide-specific T cell lines.
- Demonstration of T cell reactivity against melanoma phosphoantigens.
- Establishment of tools for further research into T cell-based cancer therapies.
Conclusions:
- Phosphopeptide-specific T cells are valuable tools for cancer immunotherapy research.
- These T cells recognize a novel class of tumor antigens.
- Further investigation can lead to improved cancer immune responses and patient survival.
